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Abstract
It is well recognized that physical and chemical properties of materials can alter dramatically at
nanoscopic scale, and the growing use of nanotechnologies requires careful assessment of unexpected
toxicities and biological interactions. However, most in vivo toxicity concerns focus primarily on
pulmonary, oral, and dermal exposure to ultrafine particles. As nanomaterials expand as therapeutics
and as diagnostic tools, parenteral administration of engineered nanomaterials should also be
recognized as a critical aspect for toxicity consideration. Due to the complex nature of nanomaterials,
conflicting studies have led to different views of their safety. Here, the physicochemical properties
of four representative nanomaterials (dendrimers, carbon nanotubes, quantum dots, and gold
nanoparticles) as it relates to their toxicity after systemic exposure is discussed.
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1. Introduction
Research involving the use of different types and designs of nanomaterials continues to evolve
with the growth of nanotechnology for in vivo applications in such fields as drug delivery,
medical imaging, diagnostics, and engineering technology [1-4]. Currently, several
therapeutics are approved for use or are in clinical trials and it is expected that nanotechnology
will be utilized in many more commercial products in the near future [4,5].
The majority of nanotoxicity studies have focused on health effects of exposure to ultrafine
(unintentionally produced) particles by inhalation, contact through skin, or ingestion [1,6-9].
These studies primarily focus on local effects (e.g. lung toxicity after particle inhalation). With
a multitude of opportunities for nanomaterial use in pharmaceutical and medical applications,
a thorough understanding of associated systemic toxicity is critical. Characterization of in
vivo toxicity has been a daunting task as nanomaterials are quite complex and conflicting
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studies have led to different views of their use and safety. This makes it difficult to evaluate,
generalize, and predict important aspects of toxicity [10]. Presented in this review are current
studies evaluating the systemic toxicity of four representative nanomaterials (dendrimers,
carbon nanotubes, quantum dots, and gold nanoparticles) as it relates to nanomaterial properties
and design.
1.1. Mechanisms of nanomaterial toxicity
Nanomaterial toxicity can occur through several different mechanisms in the body. A summary
of the major forms of in vivo nanomaterial toxicity is displayed in Fig. 1. As summarized by
Lanone et al., the main molecular mechanism of in vivo nanotoxicity is the induction of
oxidative stress by free radical formation [3]. In excess, free radicals cause damage to biological
components through oxidation of lipids, proteins, and DNA. Oxidative stress may have a role
in the induction or the enhancement of inflammation through upregulation of redox sensitive
transcription factors (e.g. NF-κB), activator protein-1, and kinases involved in inflammation
[3,11,12]. Free radicals can originate from several sources including phagocytic cell response
to foreign material, insufficient amounts of anti-oxidants, presence of transition metals,
environmental factors, and, as focused in this review, physicochemical properties of some
nanomaterials [3]. Slow clearance and tissue accumulation (storage) of potential free radical
producing nanomaterials as well as prevalence of numerous phagocytic cells in the organs of
the reticuloendothelial system (RES) makes organs such as the liver and spleen main targets
of oxidative stress. Additionally, organs of high blood flow that are exposed to nanomaterials,
such as the kidneys and lungs, can also be affected.
Intracellularly, nanomaterials may interact with cellular components, disrupt or alter cell
function, or create reactive oxygen species (ROS). Interactions of nanomaterials with the
mitochondria and cell nucleus are being considered as main sources of toxicity. As reviewed
by Unfried et al., nanomaterials such as silver-coated gold nanoparticles, fullerenes, block
copolymer micelles, and carbon nanotubes may be capable of localizing to mitochondria and
inducing apoptosis and ROS formation and that nanomaterial-induced nuclear DNA damage,
cell-cycle arrest, mutagenesis, and apoptosis is a possible source of toxicity [13]. Although
still under debate, nanomaterials may be involved in the upregulation of NADPH oxidase and
xanthine oxidase, which are free radical sources in macrophages and neutrophils [3].
Other mechanisms of toxicity from nanomaterials should be considered since nanomaterials
immediately interact with their surrounding environment. When introduced or absorbed into
the systemic circulation, interaction with blood components can lead to hemolysis and
thrombosis. Additionally, nanomaterial interactions with the immune system have been known
to increase immunotoxicity as reviewed by Dobrovolskaia et al. [5]. In the liver, further
metabolic modification of nanomaterials, e.g. by cytochrome P450, may result in
hepatotoxicity by reactive intermediates [3].
1.2. Nanomaterial design considerations
Nanomaterials have unique properties and characteristics relative to bulk materials (e.g. high
surface area to volume ratio) that may endow them with unique mechanisms of toxicity from
xenobiotics. In particular, toxicity has been thought to originate from nanomaterial size and
surface area, composition, and shape as reviewed by Lanone et al. [3].
Size plays a role in how the body responds to, distributes and eliminates materials [10,14].
Particle size can also affect the mode of endocytosis, cellular uptake, and the efficiency of
particle processing in the endocytic pathway [3,15]. In vitro studies of non-phagocytic cellular
uptake of latex spheres have demonstrated slower uptake and processing of large spheres (>200
nm) relative to small ones (50 and 100 nm) [15]. More importantly, decreasing size also leads
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to an exponential increase in surface area relative to volume, thus making the nanomaterial
surface more reactive on itself (aggregation) and to its surrounding environment (biological
components). Increased uptake into certain tissues may lead to accumulation, where they may
interfere with critical biological functions [3,7].
Chemical composition at the surface of nanomaterials will largely define their chemical
interactions since the surface is in direct contact with the body whereas the limited bulk volume
is hidden [10]. Therefore, nanomaterials behave quite differently than bulk materials. Many
nanomaterials are functionalized on the surface to increase blood circulation, make them more
biocompatible, and for targeted therapy. While functionalization has shown promise in many
applications, functional groups added to the surface can potentially interact with biological
components, alter biological function, and allow passage of nanomaterials that would not
normally be taken up by certain cells.
Degradability of the material is an important component of acute and long-term toxicity. Non-
degradable nanomaterials can accumulate in organs and also intracellularly where they can
cause detrimental effects to the cell, similar to that of lysosomal storage diseases [2]. In contrast,
biodegradable nanomaterials can lead to unpredicted toxicity due to unexpected toxic
degradation products [6]. Nanomaterials may contain transition metals (e.g. quantum dots) or
other compounds with known toxicity that are “masked” for instance by functionalization.
Degradation of this material may release toxins to the biological milieu, leading to free radical
formation and resulting in cellular damage [3,6].
As elicudated from the effects of asbestos fibers in the lungs and studies of intratracheal
instillation, nanomaterials may be capable of evading macrophage uptake and RES clearance
[8,16-18]. Although known that slow dissolution of particles can overwhelm macrophage-
mediated clearance resulting in particle persistence, the shape of nanomaterial may also play
a role in effective clearance. Recent investigations by Champion et al. have described
macrophage interaction with different shaped nanomaterials [19]. They discovered that failure
to create the required actin-driven movement of the macrophage membrane results in the
macrophage spreading onto the material rather than internalization. Therefore, complete
phagocytosis is based on the point of macrophage contact, with less internalization with rod-
like materials relative to spherical materials. Though this study was specific to alveolar
macrophages, similar results may be applicable to other tissues.
2. In vivo toxicity of nanomaterials
The uniqueness of each type of nanomaterial being explored for medical applications makes
generalization of nanomaterial toxicity rather complicated. To elucidate causes of toxicity,
current research evaluating the distribution and toxicity of nanomaterials usually focuses on
one aspect of the material properties at a time (e.g. effect of altering surface charge). Current
research on the effects of nanomaterial properties of selected types of nanomaterials is
discussed in this section with the primary nanomaterial toxicity concerns summarized in Table
1.
2.1. Dendrimers
Traditional polymer drug delivery systems utilize linear, random-coil polymers such as
polyethylene glycol, N-(2-hydroxypropyl) methacrylaminde copolymers, poly
(ethyleneimine), poly(lactic acid), poly(glycolic acid) and their copolymers, dextrin (α-1, 4
polyglucose), hyaluronic acid, chitosans, poly(glutamic acid), and poly(aspartamides) [20,
21]. The major obstacle using these polymeric materials in biomedical and pharmaceutical
applications is the heterogenic nature of these polymers. The conventional polymerization
methods for these linear polymers usually result in polymers with different chain lengths
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(molecular weights), different chemical structures, and polydispersity. Therefore, these
polymers are not reproducible batch to batch, which makes it difficult to define their in vivo
behaviors (e.g. biodistribution, pharmacokinetics, stability, toxicity) using validated
techniques. Low drug carrying capacity of these linear polymers and variable drug release
kinetics in vivo all contribute to the lack of improved therapeutic index of the loaded drug.
Dendrimers, also called arboroles or cascade polymers, are well-defined, highly branched
macromolecules with precisely controlled chemical structure and low polydispersity (Fig. 2).
Dendrimers are synthesized in a stepwise process either by a “divergent method” or
“convergent method”. In the divergent method, synthesis starts with a multifunctional core
followed by repeated addition of monomers and increase in molecular weight with exponential
increase in surface termini. By contrast, the convergent method starts from the dendrimer
surface and proceeds inward to a multivalent core where the dendrimer segments are joined
together. Dendrimer branching offers advantages such as nano-size spherical structures (for
high generations), low viscosity compared to equivalent molecular weight linear polymers,
narrow polydispersity, and high density of surface functionalities [22]. Over the past three
decades, dendrimers such as polyamidoamine (PAMAM, i.e. Starburst™) [23,24], poly
(propylenemine) (PPI) [25,26], triazine [27,28], and poly-L-lysine (PLL) [29-31] have been
used widely as vehicles for drug or gene delivery. However, the in vivo toxicity of dendrimers
has not been systematically investigated [32]. This review mainly focuses on PAMAM
dendrimers since they are one of the most studied dendrimers.
Depending on the dendrimer type and generation, they carry a positive, neutral, or negative
charge on the surface. Once introduced into the systemic circulation, positively charged
dendrimers and cationic macromolecules have been found to interact with blood components,
destabilize cell membranes, and cause cell lysis [33-35]. Roberts et al. studied the toxicity of
cationic PAMAM Starburst® in mice [24]. Cationic dendrimers of generation 3 (G3, MW
5147, diameter 31 Å, 24 amine termini), generation 5 (G5, MW 21563, diameter 53 Å, 96
amine termini), and generation 7 (G7, MW 87227, diameter 80 Å, 768 amine termini) were
given i.p. with doses ranging from 0.026 to 45 mg/kg either as a single dose or once a week
for 10 weeks. The in vivo toxicity was evaluated by behavioral abnormalities 2 h post injection
and by body weight changes up to 6 months. No significant behavioral abnormality or weight
loss was observed through the study. However, one out of five mice died at about 24 h after
dendrimer injection in the G7 group with highest dose of 45 mg/kg. These studies suggest that
low generation cationic dendrimers (G < 7) even at high doses do not cause adverse effects.
However, Heiden et al. found cationic PAMAM dendrimers (G4, amine termini) were toxic to
zebrafish embryos, and the toxicity was dose and exposure duration dependent [36]. A
mortality of 100% was observed by 24 h post fertilization when the dendrimer concentration
exceeded 20 μM. In the same study by contrast, anionic PAMAM dendrimers (G3.5, carboxylic
acid termini) were not toxic and showed no signs of attenuating embryo development. G4
dendrimers conjugated to Arg-Gly-Asp (RGD) were much less toxic compared to unconjugated
G4 dendrimers. Malik et al. also found that 95 mg/kg daily doses of anionic PAMAM
dendrimers (G3.5, carboxylic acid termini) administered i.p. led to no mortalities and no weight
change in B16F10 tumor bearing mice [37]. Overall, these studies indicated that dendrimer
toxicity is dose and generation dependent with higher dose and higher generation dendrimers
leading to more toxicity in vivo. The toxicity profiles also depend greatly on the surface charge
of the dendrimers, that is, anionic dendrimers are less toxic compared to cationic dendrimers.
Hematological toxicity is one of the most important concerns for dendrimers given
intravenously. Cationic dendrimers such as -NH2 PAMAM have shown concentration and
generation dependent hemolysis and induced morphology changes in red blood cells after 1 h
incubation at a low concentration of 10 μg/mL; whereas, anionic dendrimers were not
hemolytic at concentrations up to 2 mg/mL [23]. Agashe et al. examined the hematological
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toxicities of generation 5 PPI dendrimer (PPI-5.0G), t-BOC-protected glycine-coated
dendrimer (DBG), t-BOC-protected phenylalanine-coated dendrimer (DBPA), mannose-
coated dendrimer (M-PPI) and lactose-coated dendrimer (L-PPI) [25]. Dendrimers were
administered i.v. into male albino rats (equivalent to 1-4 mg of each polymer), and after 7 days,
blood samples were collected and analyzed to determine hematological parameters such as
white blood corpuscles (WBCs), red blood cells (RBCs), hemoglobin (Hb), haematocrit (HCT)
and mean corpuscular hemoglobin (MCH). Compared to the control group, there were
significantly higher WBC counts and lower RBC, HCT, Hb, and MCH values for the PPI-5.0G
group, probably due to the polycationic nature of the dendrimers. Surface modified dendrimers
(DBG, DBPA, M-PPI and L-PPI) showed no difference in terms of hematological parameters
compared to the control group.
Immunogenicity is the ability of antigens to induce humoral or cell-mediated immune
responses. Immunogenicity should be avoided if the immune system is not the intended target
of the dendrimer drug delivery system. The immunogenicity of PAMAM (G3, G5 and G7)
dendrimers at a dose of 5 × 10-5 mmol was studied in rabbits, and no evidence of
immunogenicity was found 10 days after i.p. injection by the immunoprecipitation assay or
the Ouchterlony double diffusion assay [24]. Five PPI-based dendrimers (PPI-5.0G, DBG,
DBPA, M-PPI and L-PPI) were injected intramuscularly into Balb/C mice at dose levels of
1-4 mg of dendrimer [25]. Blood samples were collected after 21 days and antibody (IgG) titre
was tested by ELISA. The antibody (IgG) level in blood was non-detectable, which indicated
no sign of humoral immune response triggered by the dendrimers. However, these studies only
tested short-term immunogenicity. The in vivo studies of cell-medicated immune response and
complement activation have not been reported though a G5 PAMAM dendrimer has been seen
to induce strong complement activation in vitro [38].
Nephrotoxicity and hepatotoxicity have been reported consistent with biodistribution studies
that revealed high kidney and liver accumulation for G3 PAMAM dendrimers (i.p.) [24], G3
and G4 PAMAM dendrimers (i.v. or i.p.) [23], biotinylated-PAMAM dendrimers (G0-4) (i.v.)
[39], and PEG-polyester dendritic hybrids (i.v.) [40]. Roberts et al. noticed liver cell
vacuolization of the cytoplasm in a 6-month toxicity study group after administration of G7
PAMAM dendrimers by i.p. route once a week for 10 weeks [24]. A third generation melamine
dendrimer (MW 8067, 24 amine termini) was evaluated for in vivo acute (single dose, 48 h)
and subchronic (three i.p. injections every 3 weeks over 6 weeks) toxicities [41]. The acute
study indicated the lethal dose was 160 mg/kg, giving rise to 100% mortality 6-12 h post
injection. In both acute and subchronic studies, there was no significant renal damage in all
dose ranges as determined by blood urea nitrogen levels. Hepatic function was normal at up
to 10 mg/kg dendrimer as evaluated by changes in serum alanine transaminase (ALT) activity.
However, a significant increase in ALT activity noticed for both acute and subchronic groups
at the 40 mg/kg dose level, and the histopathological investigation showed extensive liver
necrosis.
Dendrimer modification with chemically inert polyethylene glycol (PEG) or fatty acids is one
of the most attractive ways to reduce dendrimer toxicities in vitro [35,42-44]. PEG-polyester
dendritic hybrids (3-arm PEG star and G2 polyester dendrons, MW 23,500 Da) were injected
into mice as an i.v. bolus dose of 1.3 g/kg [40]. Mice survived after 24 h, and no changes of
organ pathology were observed in the liver, lungs, heart, kidney, or intestine. PEGylated
melamine dendrimer (G3, PEG 2000 termini) was administered at doses of 2.56 g/kg i.p. and
1.28 g/kg i.v. into C3H mice, and all mice survived after 24 h and 48 h after i.p. and i.v.
administration, respectively, with no liver or kidney toxicity noted [45].
The non-biodegradability of PAMAM/PPI-type dendrimers is of major concern for their
medical use. Biodistribution studies of magnetic resonance imaging (MRI) contrast agents
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based on PAMAM/PPI dendrimer-gadolinium (Gd) chelates have been reported. Lower
generations of PAMAM-Gd (diameter < 10 nm) were excreted via kidney and the renal
elimination rate decreased with increasing dendrimer size. Minimal renal excretion and high
RES uptake were observed when PAMAM-Gd size exceeded 10 nm [46-49]. It was also noticed
that only less than 15% of the injected PAMAM-Gd agents (PAMAM G4, G5, and G6) were
excreted within 2 days [49]. Dendrimer core structure also influences the biodistribution of the
dendrimer MRI agents. Compared to the PAMAM-Gd, a less hydrophilic PPI diaminobutane
core contributes to the dramatic increase in liver accumulation [50]. Although PEGylation and
other surface modification schemes may reduce the potential of harmful biological interactions,
the dendrimer core material must be biodegradable or readily eliminated by the renal or hepatic
system. Otherwise, the long-term toxicity is difficult to predict. The amide core of PAMAM
and PPI type dendrimers cannot undergo hydrolysis or enzymatic degradation. Newer
dendrimers where the core is structured from amino acids, oligonucleotides, or polyesters may
overcome these toxicity concerns [51-56].
In conclusion, in vivo dendrimer toxicity profiles are closely related to the chemical structure
of dendrimer; size and generation; exposure duration; biodistribution; and the rate, location,
and mechanism of metabolism. Toxicity of dendrimers is influenced by the nature of the
terminal groups. Full generation PAMAM dendrimers with cationic amine terminal groups are
more toxic than half-generation dendrimers with anionic carboxylic acid terminal groups. High
generations and high doses of cationic dendrimers usually lead to greater in vivo toxicity.
Surface modification with PEG or fatty acids improves dendrimer biocompatibility. In order
to design a more safe and non-toxic dendrimer drug delivery system, larger and more systematic
toxicity studies are required.
2.2. Carbon nanotubes
Carbon nanotubes (CNT) are a class of fullerenes consisting of a sheet of graphene arranged
into small cylindrical structures (Fig. 2). There at two types of CNT: single-walled (SWCNT)
and multi-walled (MWCNT). SWCNT are a single tube of graphene with a diameter ranging
from 0.4-3.0 nm and a length up to 1 μm [57,58]. MWCNT are multiple layers of tubes stacking
within each other with an overall diameter of 1.4-100 nm and can be up to several microns
long [58]. In the last few years, both SWCNT and MWCNT have been utilized as nanocarriers
for parenteral drug and gene delivery and recently as targeted cancer treatments [3,59]. The
safety of CNT is still in debate due to the lack of systematic and complete toxicity evaluation
[60]. Recently, studies have indicated that CNT responses are similar to the carcinogenic
responses of asbestos fibers when injected into the peritoneal cavity [61,62]. Due to the high
aspect ratio of CNT (>100), it is expected that CNT would behave as biopersistent fibers in
vivo. Studies have implicated size (aggregation), CNT length, and manufacturing impurities
as sources for potential toxicity in vivo and will be discussed herein.
The size of aggregated CNT is thought to be a primary concern for toxicity. Pristine (non-
functionalized) CNT are inherently hydrophobic; therefore, aggregation is expected and
observed in vivo. For injection, pristine CNT are suspended in biocompatible surfactants such
as Tween 80 or Pluronic F108 [63,64]. Several studies have been conducted on the in vivo
distribution of i.v. injected pristine SWCNT. Primarily, accumulation of CNT was determined
to be in the liver, but also in the spleen and lungs. No acute toxicity was observed in any tissues
up to 24 h [63-65]. Accumulation in the liver was suggested to be due to rapid surfactant
displacement followed by opsonization of serum proteins [63]. Yang et al. followed up
distribution studies by looking at serum biomarkers of damage. Additionally, they looked at
markers for oxidative stress (glutathione and malondialdehyde) in liver and lung samples post
dose [64]. Elevated levels of lactose dehydrogenase and alanine aminotransferase were
concluded to be due to hepatic injury from accumulation in the liver. They also found an
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increase in malondialdehyde and a decrease in glutathione in liver and lung samples (at 1.0
mg/mouse), which was indicative of increased levels of oxidative stress. Although no acute
toxicity was determined histologically up to 90 days post dose, biomarkers indicating hepatic
injury due to oxidative stress should be further investigated [64]. Studies conducted longer
than 90 days may exhibit more toxicity damage over time, similar to onset of damage from
asbestos fibers in lungs, which could take years. ROS formation and cytotoxic effects induced
by aggregates and accumulation have been observed in other studies of CNT [66,67]. A study
by Faczek et al. compared pristine SWCNT and MWCNT compatibility in muscle implants
[68]. They determined that both types of CNT formed aggregates when implanted in rat skeletal
muscle; however, MWCNT produced larger aggregates that continued to get larger over the
90-day study. SWCNT agglomerates remained the same size throughout the study and
underwent phagocytosis with subsequent drainage to the lymph nodes. MWCNT, on the other
hand, did not translocate to the lymph and remained accumulated in the muscle tissue [68].
Improper phagocytosis may be due to the large diameter of the MWCNT based on aggregation.
Reduction of CNT accumulation and aggregation is achieved by functionalization [69-71].
Rapid distribution and renal clearance from almost all tissues is observed 1-3 days after
injection of functionalized CNT, whereas pristine CNT were determined at high levels in RES
tissues up to 1 month after injection [65]. Even though functionalization of carbon nanotubes
is more promising for medical applications, current toxicity studies focus primarily on
environmental health concerns of pristine CNT. No comprehensive examination of
functionalized CNT degradation-induced toxicity has been reported, but these are important
questions as functionalized CNT have more promise as therapeutics and diagnostic tools.
Along with CNT aggregation as a function of improper macrophage uptake, the length of CNT
has been implicated as a source of improper macrophage translocation. Poland et al. studied
the effect of length on CNT toxicity by injecting MWCNT i.p. and observing carcinogenic
mechanisms in the abdominal cavity and on the diaphragm [61]. The longer length (≥ 20 μm)
CNT resulted in an inflammatory response within 24 h with consequent granuloma 7 days after
injection. These longer lengths may cause carcinogenic effects such as mesotheliomas, if longer
studies were conducted. In the same study, shorter lengths of i.p injected MWCNT were
effectively taken up by macrophages with efficient phagocytosis. In terms of CNT for
therapeutics, it can be deduced that SWCNT may be more favorable than MWCNT from a
toxicology standpoint due to smaller size and length resulting in less aggregation and better
uptake by macrophages. Hirano et al. further suggested that MWCNTs are recognized and
interact with macrophage receptors on the plasma membrane and can rupture the membrane
causing cytotoxicity and damage to the macrophage [72].
Methods of CNT fabrication and purification have been shown to increase toxic effects of
CNT. Arc-discharge, laser ablation, chemical vapor deposition, and high-pressure carbon
monoxide synthesis are methods commonly used to fabricate CNT [69,73]. These methods are
often performed in the presence of metal catalysts with CNT growth occurring on solid
supports. Impurities such as residual metal or supports and amorphous carbon in the final
formulation have been thought to induce oxidative stress. On the other hand, extensive
purification and treatment will also cause degradation of the nanotubes [73]. Therefore, a fine
balance between synthetic methods and purification must be achieved to fabricate highly
purified CNT for injection.
Low clearance and accumulation of CNT in vivo warrants studies to determine chronic
exposure toxicity. Radiolabeled isotopes are commonly used to evaluate the in vivo
performance of CNT [70,71]. However, due to isotopic decay and degradation of the label from
the CNT, radiolabeling suffers from short study timeframes. Recently, Liu et al. and Cherukuri
et al. have used Raman spectroscopy and near-infrared fluorescence, respectively, for intrinsic
detection of CNT in tissue homogenates, urine, and feces samples [63,69]. Yang et al.
Aillon et al. Page 7













determined that pristine SWCNT remained stable up to 28 days in lungs, liver, and spleen by
TEM visualization in mice that were injected i.v. with a high dose of CNT [64]. Therefore,
estimation and evaluation of chronic exposure toxicity may be possible based on evaluation of
CNT intrinsic properties.
In conclusion, toxicity concerns of general CNT use in vivo have stemmed from observed
toxicity after delivery to the lungs. Current studies have shown that once in the bloodstream,
intrinsic properties, propensity to aggregate, and slow clearance can lead to oxidative stress
especially in the liver, lungs and spleen, ultimately resulting in inflammation. More
importantly, the length of CNT has been shown to result in inefficient phagocytosis and damage
to macrophages. Due to less aggregation and shorter lengths, SWCNT are better suited for in
vivo applications over MWCNT. Functionalization of SWCNT further reduces aggregation;
however, more thorough research on functionalized CNT toxicity will need to be conducted.
Moreover, methodically conducted experiments that mimic chronic exposure to CNT will be
more productive in the determination of CNT nanotoxicity.
2.3. Quantum dots
Quantum dots (QDs) are fluorescent semiconductor nanocrystals (~ 2-100 nm) with unique
optical and electrical properties [74,75]. QDs possess high brightness due to their extinction
coefficient and quantum yield, broad absorption characteristics, narrow line width in emission
spectra, continuous and tunable emission maxima due to quantum size effects, and a longer
fluorescence lifetime with negligible photobleaching over minutes to hours [76-79]. These
properties make QDs advantageous in biotechnology and medical applications as optimal
fluorophores for in vivo biomedical imaging and for targeting specific cells (e.g., labeling
neoplastic cells, peroxisomes, DNA, and cell membrane receptors) after conjugation with
specific bioactive moieties [80-85]. These applications are predicted to grow because of their
numerous advantages over alternative biological labeling moieties (e.g. fluorescent dyes and
radioisotopes).
QDs have a metalloid crystalline core (e.g. CdSe) and a shell (e.g. ZnS) that shields the core
(Fig. 2) [86]. The core consists of a variety of metal complexes such as semiconductors, noble
metals, and magnetic transition metals [87,88]. The shell, formed on the metalloid core during
synthesis in organic solvents, makes QDs hydrophobic, and hence limits their use in biological
applications. To make QDs biocompatible, secondary coatings are added that improve water
solubility, QD core durability, and suspension characteristics. These organic coatings can be
used towards targeting biological components for diagnostic or therapeutic purposes [89].
The safety of metals and their use in vivo is an ongoing topic of debate. Divalent cations are
known to be toxic, even at low concentrations in the body. Due to reabsorption and
accumulation in the kidneys, the main problem with heavy metals is nephrotoxicity [90]. For
example, gadolinium-based contrast agents for clinical MRI analysis have been reported to be
associated with acute renal failure [91]. Some researchers have considered QDs to be inert
structures where the metallic core is safely passivated, while others have dismissed the use of
QDs in vivo because of potential toxicity. Cadmium and selenium, two of the most used metals
in QD cores, are known to cause acute and chronic toxicities in vertebrates and are of significant
health and environmental concern [92]. Cadmium has a biological half-life of 15-20 years in
humans, accumulates in tissues, and can cross the blood-brain barrier and the placenta. In the
case of QDs, release of Cd2+ from the core and generation of ROS and oxidative stress appears
to be the mechanism of in vivo toxicity [93,94]. Although researchers agree on the toxicity of
Cd2+, conflicts remain on the use of QDs in vivo. Studies have suggested that the shell (most
commonly ZnS) along with secondary coatings prevent Cd2+ leakage from the core [95]. Others
suggest that Cd2+ can leak from the core with QD complex instability. Arguments of QD safety
can be somewhat confusing because of the variety of QDs being synthesized and considered.
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Studies concluding that QDs are toxic indicate that toxicity may originate from QD stability,
size, surface charge, and type of surface coating.
Possibly the most important aspect of QD toxicity is the stability of the core/shell/coating
complex. Stable complexes should protect the body from core metal toxicity. Several studies
suggested that under oxidative and photolytic conditions, QD are labile and subject to
degradation, thus exposing the potentially toxic shell material, intact core metalloid complex,
and core metal components (e.g. Cd, Se) [75]. It has been reported that Cd2+ released under
oxidative attack can bind to the sulfhydryl groups of critical mitochondria proteins leading to
mitochondria dysfunction and ultimately cell poisoning [92]. Addition of the secondary surface
coating renders QDs biocompatible and can help protect against degradation of QDs, but the
method of functionalization (e.g. electrostatic, adsorption, multivalent chelation, or covalent
bonding) and the coating composition are important when considering QD durability, stability,
and in vivo reactivity [75]. Interestingly, a recent communication by Mancinci et al. suggests
an oxidative mechanism wherein hypochlorous acid and hydrogen peroxide, both produced by
phagocytic cells, may diffuse across polymeric secondary coatings and cause QD lattice defects
and solubility of the core [96]. Therefore, there may be in vivo oxidative mechanisms of QD
degradation regardless of the presence of stable secondary coatings.
Some studies have suggested that QD size is the source of toxicity regardless of the presence
or absence of secondary coating. Shiohara et al. studied the cytotoxicity of CdSe/ZnS coated
with mercaptoundecanoic acid (MUA), resulting in a carboxyl-QD, in three different cell lines.
They determined that increased cell death correlated with a decrease in QD size even at low
concentrations [78]. These results were consistent with studies by Zhang et al. supporting
increased cytotoxicity with small sized QDs in rat hepatocytes [97].
Since a secondary coating is almost always used for in vivo applications, many studies have
focused on what roles coatings play on QD stability relative to nanoparticle toxicity [95]. To
assess the importance of surface charge, many groups have studied the toxicity of cationic
(amine) and anionic (carboxyl) secondary coatings on QDs. Geys et al. conducted an acute in
vivo toxicity study on amine- and carboxyl-coated commercially available CdSe/ZnS QDs.
Low doses of 1.44 pmol or 14.4 pmol of both types did not elicit acute adverse effects. However,
at high doses the QDs caused pulmonary vascular thrombosis, with carboxyl-QDs being more
potent in inducing this effect than amine-QDs. Because fibrin fibers were present in the thrombi
and because pretreatment with heparin abolished the thrombotic effects, they speculated that
negatively charged QDs activated the coagulation cascade via contact activation [98]. Hoshino
et al. coated CdSe/ZnS with mercaptoundecanoic acid (MUA) (QD-COOH), cysteamine (QD-
NH2), thioglycerol (QD-OH), QD-OH/COOH and QD-NH2/OH to assess the effects of surface
charge on the cytotoxicity of hepatocytes. They found that the highly negative charge QD-
COOH induced DNA damage after 2 h while the other types have no significant cellular damage
[99]. They suggest that after endocytosis, the acidic nature of the endosome creates QD-COOH
instability in the cell where QDs can easily aggregate. However, only amine-QDs were stable
in acidic conditions (100 nM QD incubated in glycine buffer (pH = 3.0) for 30 min at room
temperature) [100]. Overall, a balance of surface charge should be considered in evaluating
potential stability and toxicity issues.
The type of secondary surface coating may affect the toxicity of the QD complex. Polyethylene
glycol (PEG), a common pharmaceutical excipient, is used extensively in commercially
available QDs. Ballou et al. prepared QDs coated with amphiphilic polyacrylic acid and
simultaneously conjugated to different molecular weights of PEG (750 and 5000). By
monitoring QDs in mice with fluorescent imaging, they found that significant liver uptake was
visible even at 1 min using (750)-PEG-QD, but completely cleared away after 1 h, while (5000)-
PEG-QD was absorbed by liver in 1-3 h post-injection. They determined no significant liver
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toxicity; however, they found differences in accumulation and clearance [101]. A longer study
(28 days) was carried out by Yang et al. on a commercially available QD, (5000)-PEG-ZnS/
CdTe (QD705, about 13 nm). After a single i.v. injection in mice, they demonstrated that the
liver and spleen were the main accumulative organs. QDs were not detected in either urine or
feces, which would suggest accumulation of QDs with high molecular weight PEG [89]. When
PEG-QDs are injected subcutaneously, QDs clear from the site of injection and accumulate in
the regional lymph nodes along with the liver, spleen, and kidney [102]. Therefore, the type
of injection would need to be considered for QD accumulation and toxicity [75,103]. Albumin
is another commonly used secondary coating for QD in vivo applications. Fisher et al. coated
CdSe/ZnS with MUA/ lysine to form QD-LM (about 25 nm) or coated the QD-LM with bovine
serum albumin (BSA) to form QD-LM-BSA (about 80 nm). After i.v. injection in the rat, both
QDs were mainly detected in the liver, although QDs were detected in the spleen, lung, kidney,
and bone marrow. However, the QD-LMBSA liver uptake was greater (99%) relative to the
QD-LM uptake (40%). This corresponded with a faster blood clearance of QD-LM-BSA.
Neither type of QD was detected in the urine or feces up to 10 days, which would suggest
accumulation in the liver, especially with BSA conjugation [104]. Overall, most studies have
indicated that differences in coating material and size lead to changes in pharmacokinetics and
can potentially cause toxicity.
In conclusion, the potential toxic effects of QDs have become a hot issue that must be further
addressed before clinical applications would be possible. Most studies recommend that not all
QDs are similar in their toxicity, and toxicity of differing QDs must be considered individually.
The adverse effects of QD can be mitigated or eliminated by proper choices of coating materials
and modification techniques that reduce QD instability.
2.4. Gold nanoparticles
Due to a straightforward synthesis, stability, and ease of incorporation of functional groups for
targeting capabilities, gold nanomaterials have great application in gene and protein delivery,
biological imaging, cancer treatments, and in implants (e.g. pacemakers and stents)
[105-107]. Additionally, gold has been used as anti-inflammatory and anti-rheumatic agents
(Auranofin® and Tauredon®) in the treatment of rheumatoid arthritis [107]. Many studies have
suggested that gold nanomaterials are bioinert and can be used safely. This thought may be
due to the established safety of bulk gold materials, but as the size decreases into the nanoscopic
dimensions, gold will behave very differently than in bulk. Some research has found gold to
be toxic in the body, where elemental gold can undergo oxidation or become soluble by
cyanidation [108,109]. Studies have shown that gold is heavily taken up by the kidneys, causing
nephrotoxicity, and can also initiate eryptosis (erythrocyte suicidal death) [110,111]. Studies
have suggested that the size, surface charge, and shape are key factors related to potential
toxicity of medicinal gold complexes.
Several studies have examined the effect of gold nanoparticle size on toxicity. Specifically,
gold nanoclusters (illustrated in Fig. 2) of 1.4 nm have been shown to selectively and
irreversibly bind to the major grooves of B-DNA and cause increased cytotoxicity compared
to larger particles (18 nm). The lack of interaction of larger particles with DNA is suggested
to be due to steric hindrance. While gold nanoclusters may be very effective cancer treatments,
healthy cells would also be affected potentially causing toxicity [112,113]. Similarly, Pan et
al. studied the size-dependent cytotoxicity of gold nanoparticles (water soluble and stabilized
with triphenylphosphine derivatives) on several different cell lines. They discovered that
nanoclusters of 1.4 nm exhibited increased cytotoxicity (IC50= 30 and 46 μM), whereas
nanoclusters of 0.8, 1.2, and 1.8 nm where four to six-fold less toxic. Larger sizes (15 nm)
exhibited no cytotoxicity even at high concentrations (6.3 mM) [114]. Moreover, Chithrani et
al. examined the uptake of 14, 50, and 74 nm sized citric acid ligand stabilized gold
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nanoparticles into HeLa cells and determined that 50-nm spheres were more quickly taken up
by endocytosis than both the smaller and larger sizes [115]. They further studied the rate of
exocytosis of transferrin-coated gold nanoparticles and determined that the rate of exocytosis
was size-dependent with more accumulation of larger gold nanoparticles in the cell [116].
When studying the effect of gold nanoparticle size after i.v. injection of colloidal gold in mice,
smaller particles (10-50 nm) were found to disperse quickly to almost all tissues, mainly
accumulating in the liver, lungs, spleen, and kidneys at 24 h post injection. Larger particles
(100-200 nm) were found in the liver, lungs, spleen, and kidneys, but they were not as widely
dispersed into other tissues as were the smaller particles. These studies concluded a size-
dependent distribution and potential toxicity of smaller (< 50 nm) gold nanoparticles [105,
117].
To condense and deliver pDNA successfully, synthetic gene transfection vectors generally
must be cationic. Sandhu et al. determined that cationic gold nanoparticles were 8-fold more
efficient as a non-viral gene vector over the commonly used polymer polyethyleneimine
[118]. Goodman et al. examined the effects of gold nanoparticle surface charge on cytotoxicity
by studying cationic (amine) and anionic (carboxyl) gold nanoparticles on Cos-1 cells, red
blood cells, and E. coli. It was concluded that cationic gold particles were moderately toxic
and anionic particles were nontoxic, suggesting the initial electrostatic binding of the particles
to the negatively charged cell membrane as a probable mechanism of toxicity and that
electrostatic repulsion may limit anionic and neutral particle interaction with the cell surface
[119]. So, cationic gold nanoparticles can be expected to exhibit more toxic effects relative to
anionic particles. However, this would need to be performed in vivo for a better assessment of
the effects of surface charge on biological interaction and gold nanoparticle toxicity.
Gold nanomaterials can be found in many different shapes, especially as spherical clusters and
nanorods. Along with size, Chithrani et al. studied the effect of shape on the cellular uptake of
gold nanoparticles. They concluded that both nanorods (74 × 14 nm) and spherical particles
(74 and 14 nm) are taken up by cells; however, nanorod uptake is slower relative to spherical
particles in HeLa cells [115]. Wang et al. further concluded that nanorods are more cytotoxic
than spherical gold nanomaterials to human HeCaT keratinocytes [120]. Although both studies
concluded differences between spherical particles and nanorods, both Chithrani et al. and Wang
et al. suggested that the more important difference in cellular uptake rates and cytotoxicity was
the use of different chemistries to stabilize the gold nanomaterials. During synthesis,
cetyltrimethylammonium bromide (CTAB) is a commonly used cationic surfactant to stabilize
gold nanorods. Although aggregation of gold nanorods has been shown intercellularly,
nanospheres also show aggregation without causing cytotoxicity [120,121]. This led to future
investigation into the toxicity of CTAB with several studies recognizing it as a main source of
toxicity of gold nanorods [120-122]. CTAB surface reduction has been achieved by
displacement of CTAB with PEG, citric acid ligands, and by coating gold nanoparticle surfaces
with transferrin. Studies have concluded that these modified gold nanoparticles do not exhibit
cytotoxic effects, although the amount of displaced CTAB is difficult to quantify with current
analytical methods [115,120-123]. In vivo studies on the effects of CTAB and aggregation of
gold nanomaterials will need to be evaluated, as well as more complete studies on the effects
of gold nanoparticle shape on toxicity. Additionally, alternative means to stabilize gold
nanorods need to be considered.
In conclusion, gold nanoparticles have numerous medical applications and traditionally have
been thought of as bioinert since bulk gold has been deemed as such. However, more studies
are suggesting potential toxicity concerns for gold nanoparticles due to their size, surface
charge, and shape - the same unique properties that make them so appealing for medical
applications. Unfortunately, most of the studies suggesting toxicity of gold nanoparticles come
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from in vitro experimentation. Thorough distribution and toxicity studies are critically needed
to fully evaluate gold nanoparticles for in vivo use.
3. Analysis of nanomaterial toxicity
As current studies show conflicting results on safety and biocompatibility of nanomaterials, it
is recognized that validation of analytical methods used to determine toxicity is necessary.
Since engineered nanomaterials are so unique and complex, standardizing analytical methods
for nanoparticle characterization is rather complicated. As reviewed by Hall et al., complete
evaluation of nanoparticles for therapeutic use include thorough physicochemical property
characterization, sterility and pyrogenicity assessment, biodistribution, and toxicity
determination (both in vitro and in vivo) [124].
Powers et al. recognized that material properties are complicated by the behavior of the material
in biological environments and that traditional methods of characterizing powder forms of
nanomaterials may be ineffective for characterizing materials in biological systems. They
proposed key characteristics that should be evaluated and reviewed analytical methods of
measuring nanomaterial size and shape, dispersion, physicochemical properties, surface area,
porosity, and surface [14]. In particular, it was suggested that transmission electron microscopy
(TEM) and dynamic light scattering (DLS) would be suitable techniques for size and shape
measurements in biological systems [14,124]. TEM and DLS was successfully applied to a
study by Murdock et al. to characterize aggregation of various nanomaterials in water and
culture media (with and without serum) [125].
In vivo distribution and toxicity examinations should include studies such as initial disposition,
therapeutic efficacy, and dose-response studies, at a minimum. Distribution studies have been
conducted where nanomaterials were tracked in the blood and tissues by conjugating the
material with a radiolabel or organic dye, if direct detection of the material was not achievable.
Degradation of the conjugate and the inevitable radiolabel decay or dye quenching limit this
technique for toxicity studies where long-term evaluations are necessary. If possible, detection
based on the material intrinsic properties is preferred, especially if the material is stable, to
avoid misleading results [69]. However, since metabolism and degradation is often observed
with nanomaterials used in vivo, detection strategies for analysis of all major parts of the
nanomaterial, although challenging, would be the most ideal approach (i.e. a multi-indicator
approach) [6,124]. Currently, toxicity assessments are performed by probing for inflammation.
Tissue histological examination for immune response is traditionally performed, with some
studies of overall animal behavior and weight loss as indicators of material intolerance.
Moreover, analysis of biomarkers of inflammation, cell viability, and oxidative stress
generation would enhance mechanistic studies into nanomaterial toxicity [65]. A summary of
the conducted toxicity in vivo toxicity studies of the four presented nanomaterials is displayed
in Table 2.
4. Summary, conclusions and future challenges
Although studies are conflicting regarding the magnitude and mechanisms of nanomaterial
toxicity, it is evident that some nanomaterials that were previously considered biocompatible
due to safety of the bulk material may indeed be toxic. Nanomaterial size, shape, surface
chemistry, and degree of aggregation influence the production of free radicals and subsequent
oxidative stress. Nanoparticle toxicology is a relatively young field, and the bulk of reports
have focused on acute toxicity. Long-term toxicity of the materials and examination of chronic
exposure are critical to understanding the toxicology of nanomaterials in vivo. Evaluation of
toxicity has proven to be challenging as several factors may be working in tandem to cause
nanoparticle toxicity. Furthermore, as nanomaterials are inherently quite complex, many
unexpected interactions (based on bulk properties) with biological components may arise.
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However, with appropriately validated analytical methods and carefully designed
experimentation, the mechanisms of toxicity may become clearer so that nanomaterials can
safely be used as therapeutics and as diagnostic tools.
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Major forms of in vivo nanomaterial toxicity
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Schematic of the structures of a) dendrimers of varying generations, b) carbon nanotubes, c) a
quantum dot and d) a gold nanocluster
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Table 1
Summary of primary causes of nanomaterial toxicity in vivo
Nanomaterial Type Primary Toxicity Concerns Reference
Dendrimers Surface charge [24] [25] [36] [37]
Size (generation) [24]
Carbon nanotubes Size (aggregation) [63-68]
Length [61] [62] [72]
Quantum dots Stability of core/shell/coating [75] [92] [96]
Type and surface charge of coating [75] [89] [99-101] [103] [104]
Gold nanoparticles Size [105] [112-117]
Shape [115] [120-122]
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Table 2
Summary of the conducted in vivo toxicity studies
Nanomaterial Toxicity Study Analyzed Parameters Study length Reference
Dendrimers General toxicity Behavior, weight change,
mortality
24 h - 6 months [24] [37] [40]
[45]
Hematological toxicity Complete blood count 7 days [25]
Immunogenicity IP, ODD, Antibody (IgG) titre
by ELISA
21-52 days [24] [25]
Hepatotoxicity Histology, serum ALT 48 h - 6 months [24] [41]
Nephrotoxicity BUN 48 h - 6 weeks [41]
Carbon nanotubes PK and distribution Radiolabel 24 h -18 days [70] [71]
TEM of tissues, urine & feces 90 days [64] [65] [61]
Raman spectroscopy 90 days [64] [69]
Near-infrared fluorescence 24 h [63]
Tissue inflammation Histology 7 - 90 days [61] [64] [68]
Hepatic function Serum LDH, TBIL, ALT, AST 90 days [64]
Oxidative stress Tissue glutathione & MDA
levels
90 days [64]
Quantum dots PK and distribution TEM of tissues 90 min - 24 h [101] [104]
Weight change 28 days [89]
ICP-MS of tissue homogenates 3 hrs - 28 days [89] [104]
Fluorescence spectroscopy 28 days [89]
Gold nanoparticles PK and distribution ICP-MS of tissue homogenates 24 h [105] [117]
*IP = Immunoprecipitation; ODD = Ouchterlony double diffusion; ALT = alanine aminotransferase; BUN = blood urea nitrogen; LDH = lactose
dehydrogenase; TBIL = total bilirubin; AST = aspartate aminotransferase; MDA = malondialdehyde
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